intravitreal injection of conbercept
PreclinicalProtein / enzyme
intravitreal injection of conbercept is one of 36 small molecule programs targeting Vascular Disease. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Vascular Disease
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Repatha
AmgenApproved
Precose
BayerApproved
Colcrys
Jazz PharmaceuticalsApproved
Letairis
GileadApproved
Xarelto
WWim Janssens
Approved
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Andriol
AAuxilium
Approved
Aricept
EisaiApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Proliferative Diabetic Retinopathy1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Preclinical[1]
- Company
- SSun Yat-sen University